ISSN No:-2456-2165

# Progress in ATTR-CM: A Detailed Exploration of Pathophysiology, Diagnostics, and Treatment Approaches

NAVEEN V*[1]; FELIC S[1]; ABISHEK P[1]
[1]Doctor of Pharmacy, Department of Clinical Pharmacy Practice,
JKKMMRF'S Annai Jkk Sampoorani Ammal College of Pharmacy, Komarapalayam, Tamilnadu, India.

Corresponding Author: NAVEEN V
Doctor of Pharmacy, Department of Clinical Pharmacy Practice,
JKKMMRF'S Annai Jkk Sampoorani Ammal College of Pharmacy, Komarapalayam, Tamilnadu, India. 638183

**Abstract:- Transthyretin amyloid cardiomyopathy (ATTR-CM) represents a progressive and underrecognized condition driven by the deposition of misfolded transthyretin (TTR) amyloid fibrils in the heart. Through this review, we aim to explore the complexities of ATTR-CM, including its classification into wild-type (wtATTR), predominantly affecting older males, and hereditary (hATTR), linked to over 120 pathogenic TTR gene variants such as Val30Met and Val122Ile, which is notably common in individuals of African descent. The subtle and often non-specific nature of its symptoms underscores the challenges in timely diagnosis.**

**Advances in diagnostic techniques, including Tc-99m PYP scintigraphy and PET imaging, have transformed non-invasive detection, facilitating early identification and differentiation from other amyloidosis types. We discuss the impact of therapeutics like tafamidis, a TTR stabilizer, which has improved survival rates and reduced hospitalizations, while emphasizing the urgent need to address healthcare disparities that limit access to these advancements in certain populations. This review delves into the molecular underpinnings of ATTR-CM, highlighting the pathological progression from TTR monomer misfolding to the formation of toxic oligomers and amyloid fibrils that disrupt mitochondrial function and myocardial integrity. We evaluate emerging therapeutic approaches, such as fibril-disrupting agents and gene-editing technologies, and their potential to redefine treatment paradigms. By synthesizing the latest insights, we aim to provide a comprehensive overview of ATTR-CM, emphasizing the integration of advanced diagnostics, personalized therapeutics, and health equity to guide future research and clinical practice.**

***Keywords:-*** *Transthyretin Amyloid Cardiomyopathy (ATTR-CM); Amyloidosis; TTR (Transthyretin); Wild-type ATTR (wtATTR); Hereditary ATTR (hATTR); Diagnostic Imaging; Tafamidis; Gene Silencing Therapies; CRISPR-Cas9; Heart Failure with Preserved Ejection Fraction (HFpEF)*

## I. INTRODUCTION

Misfolded transthyretin (TTR) amyloid fibrils deposit in the heart, causing transthyretin amyloid cardiomyopathy (ATTR-CM), an underdiagnosed, potentially fatal, progressive illness. Transporting thyroxine and retinol-binding protein is the function of TTR, a tetrameric transport protein mostly generated by the liver. Destabilized TTR tetramers in ATTR-CM separate and misfold into amyloid fibrils, which enter the heart and result in a restrictive cardiomyopathy that affects diastolic function and ultimately causes heart failure [1]. There are two different kinds of ATTR-CM: wild-type (wtATTR) and hereditary (hATTR). Over 120 pathogenic variants in the TTR gene have been found to cause hereditary ATTR-CM, with Val30Met and Val122Ile being the most prevalent. Depending on the mutation, this type can manifest as early as the third or fourth decade, with various degrees of penetrance and organ involvement [2,3]. Formerly known as senile systemic amyloidosis, wild-type ATTR-CM mainly affects elderly males and usually manifests after the age of 65. It is not linked to any genetic alterations. It is becoming more well acknowledged as a major factor contributing to heart failure with preserved ejection fraction (HFpEF) [4]. When ATTR-CM patients experience non-specific symptoms including peripheral edema, tiredness, and dyspnea, they frequently present with mild clinical presentations that might be confused with other types of heart failure. Furthermore, extracardiac symptoms commonly occur before cardiac involvement by many years, such as carpal tunnel syndrome, lumbar spinal stenosis, and autonomic dysfunction; this frequently results in missing or delayed diagnosis [5,6]. As a result, historically, the diagnosis of ATTR-CM has been difficult and typically calls for a high index of suspicion. However, new developments in diagnostic imaging, including scintigraphy with technetium-99m pyrophosphate (Tc-99m PYP), have transformed the non-invasive diagnosis of ATTR-CM and made it possible to distinguish it from other types of cardiac amyloidosis, especially light-chain amyloidosis (AL) [7]. This approach eliminates the requirement for endomyocardial biopsy, which was once thought to be the gold standard, and allows for a prompt and reliable

ISSN No:-2456-2165

diagnosis in situations of suspected hereditary disease when combined with genetic testing [8]. Treatment-wise, the introduction of disease-modifying medications has brought about major advancements. Significant reductions in mortality and hospitalizations associated to cardiovascular disease have been observed in both hereditary and wild-type variants of ATTR-CM with the TTR stabilizer tacamidis, according to critical clinical trials [9]. Targeting the underlying amyloidogenesis by lowering TTR production, other novel treatment approaches, including as gene silencing medicines (patisiran and inotersen), are being considered.Other cutting-edge therapeutic strategies, like as gene-silencing medications (patisiran and inotersen), are being studied in order to target the underlying amyloidogenesis by reducing TTR synthesis [10].

## II. OVERVIEW OF AMYLOIDOSIS

### *A. Definition of Amyloidosis*

A rare and complicated condition known as amyloidosis is defined by the aberrant build-up of amyloid proteins in different tissues and organs, which can cause serious organ malfunction. Depending on the organs impacted, these amyloid deposits can cause a variety of clinical symptoms. They are created when misfolded proteins accumulate and impair regular cellular activity. Organs include the heart, kidneys, liver, and neurological system may be affected by the illness, which may result in serious and sometimes fatal complications [12,13].

### *B. Role of Transthyretin (TTR) Protein*

Transport of thyroid hormones (such thyroxine) and retinol (vitamin A) is the main function of transthyretin (TTR), a protein mostly generated by the liver. TTR plays a crucial role in the amyloidosis context because it has the ability to misfold and produce amyloid fibrils, which induce transthyretin amyloidosis (ATTR). There are two varieties of this condition: wild-type (wtATTR), which develops naturally as people age and is not linked to genetic alterations, and hereditary (hATTR), which is brought on by mutations in the TTR gene. Progressive organ damage, namely to the heart and peripheral nerves, can be caused by the buildup of TTR amyloid fibrils [14,15].




Fig 1 This Flowchart Illustrating the Classification of **Cardiac Amyloidosis**, a Condition Characterized by the Buildup of Amyloid Proteins in the Heart [11].

## III. FORMATION OF AMYLOID DEPOSITS FROM MISFOLDED TRANSTHYRETIN PROTEINS

### *A. Misfolding of TTR*

The TTR protein may misfold in specific circumstances, such as age-related alterations in wild-type transthyretin amyloidosis or genetic mutations in hereditary transthyretin amyloidosis. Normally hidden hydrophobic portions of the protein are exposed as a result of this misfolding, which alters the protein's usual structure and function [16,17].

### *B. Aggregation*

The exposed hydrophobic regions of the misfolded TTR proteins cause them to cluster. Small oligomeric structures can be formed by the interactions between these proteins. Compared to the correctly folded protein, these oligomers are less stable and have the ability to further aggregate into bigger fibrils [18,19].

### *C. Fibril Formation*

Amyloid fibrils, which have a structure rich in beta sheets, are formed by the oligomers as they continue to assemble. Hydrogen bonds and hydrophobic interactions are two examples of the intermolecular forces that promote this transition. This can result in tissue deposition when the resultant amyloid fibrils build up in extracellular spaces [20,21].

*D. Tissue Damage*

Amyloid fibril buildup causes inflammation, cellular stress, and ultimately organ malfunction by interfering with normal cellular processes. Frequently impacted organs including the heart, kidneys, and neurological system [22,23].

## IV. TYPES OF ATTR-CM

Table 1. This table Summarizes the Two Types of Transthyretin Amyloidosis (ATTR): **Wild-Type ATTR (ATTRwt)**, Typically seen in Older Males without Genetic Mutations, and **Hereditary ATTR (ATTRv)**, Caused by TTR gene Mutations. Diagnosis of ATTRwt is Challenging and Relies on Advanced Imaging, While ATTRv Benefits from Genetic Testing and Family History Assessment.

| Type | Cause | Common Age of Onset | Diagnosis | Key Features | Reference |
|---|---|---|---|---|---|
| **Wild-Type ATTR (ATTRwt)** | Misfolding of transthyretin protein without genetic mutations | Typically >60 years, more common in males | Challenging due to similarity with other heart diseases; advanced imaging and cardiac scintigraphy are essential | Common in older individuals; increasing recognition as a significant cause of heart failure in the elderly | [24,25,26,27,28] |
| **Hereditary ATTR (ATTRv)** | Mutations in the TTR gene causing unstable TTR protein, leading to amyloid fibril formation | Variable, depending on mutation | Early diagnosis facilitated by genetic testing and family history | More aggressive disease course; requires family screening and genetic counseling | [24,25,26,27,28] |

## V. PATHOPHYSIOLOGY

*A. Molecular Pathways Influencing TTR Tetramer Dissociation and Stabilization Mechanisms*

Molecular pathways involved in the dissociation of transthyretin (TTR) tetramers are critical to understanding the mechanisms underlying TTR amyloidosis. TTR exists as a stable tetramer under physiological conditions, but various factors can induce its dissociation into monomers, which are prone to aggregation and amyloid formation. One significant pathway driving this dissociation is the influence of pH and the presence of destabilizing conditions. For instance, studies have shown that lowering the pH can lead to the dissociation of TTR tetramers into monomeric intermediates, which subsequently misassemble into amyloid fibrils [30,35]. The thermodynamic stability of TTR is also affected by oxidative modifications, which can enhance its amyloidogenicity. Specifically, oxidized forms of TTR exhibit reduced stability compared to their non-oxidized counterparts, making the dissociation process more favorable [38,34]. Oxidative stress plays a pivotal role in modulating the stability of TTR. Age-related oxidative modifications have been linked to increased amyloidogenicity, as these modifications can destabilize the tetramer structure, thereby facilitating its dissociation [38,29]. The dissociation of TTR tetramers is often considered the rate-limiting step in the aggregation pathway leading to amyloid formation [36,37]. Furthermore, the presence of reactive oxygen species can exacerbate the destabilization of TTR, promoting the formation of aggregation-prone monomers [29]. Molecular chaperones also contribute significantly to the stabilization of TTR tetramers. Chaperones such as clusterin have been shown to enhance the stability of TTR by preventing its aggregation and promoting proper folding [33]. Small molecules, including certain flavonoids and non-steroidal anti-inflammatory drugs like diflunisal, have been identified as kinetic stabilizers of TTR tetramers. These compounds bind to TTR and stabilize its native conformation, thereby reducing the likelihood of dissociation and subsequent aggregation [31,32]. The interaction of these stabilizers with TTR can mitigate the effects of oxidative stress, further enhancing the protein's stability under pathological conditions [33]. In summary, the dissociation of TTR tetramers is influenced by various molecular pathways, including pH changes and oxidative stress, which destabilize the tetrameric structure. Conversely, molecular chaperones and small-molecule stabilizers play crucial roles in maintaining TTR stability, thereby preventing the pathological consequences associated with its dissociation and aggregation.

*B. Differential Toxicity of Soluble Oligomers and Mature Fibrils: Implications for Myocardial Injury, Mitochondrial Dysfunction, and Calcium Dysregulation*

The differential toxicity of soluble oligomers versus mature fibrils has significant implications for myocardial injury mechanisms, particularly concerning mitochondrial dysfunction and calcium dysregulation. Research indicates that soluble oligomers are generally more toxic than their mature fibril counterparts, which can be attributed to their ability to disrupt cellular processes more acutely and effectively. Soluble oligomers, such as those formed from amyloid beta (Aβ), have been shown to induce mitochondrial dysfunction through various mechanisms. For instance, Aβ oligomers can cause mitochondrial fragmentation and impair mitochondrial transport, leading to a reduction in mitochondrial density in neuronal processes [39,40]. This fragmentation is linked to the activation of dynamin-related protein 1 (Drp1), which is

crucial for mitochondrial fission [40]. Furthermore, oligomers can interact with mitochondrial membranes, leading to the opening of the permeability transition pore and subsequent mitochondrial depolarization, which is a precursor to cell death [41]. The disruption of mitochondrial function is critical, as it can lead to decreased ATP production and increased production of reactive oxygen species (ROS), exacerbating cellular injury [42]. In addition to mitochondrial dysfunction, soluble oligomers also contribute to calcium dysregulation. Aβ oligomers have been shown to promote excessive calcium influx through ionotropic glutamate receptors, particularly NMDA receptors, which can activate the mitochondrial calcium uniporter [43]. This overload of calcium within mitochondria can trigger a cascade of events leading to mitochondrial dysfunction, including increased ROS production and membrane depolarization [43]. The dysregulation of calcium homeostasis is particularly detrimental in cardiac myocytes, where precise calcium signaling is essential for contractile function. The resultant calcium overload can lead to arrhythmias and further myocardial injury [44]. In contrast, mature fibrils, while still toxic, tend to have a different mechanism of action. They are often less soluble and do not readily interact with cellular membranes in the same way that oligomers do. Studies suggest that mature fibrils may contribute to toxicity through mechanisms such as mechanical disruption of cellular structures or by seeding further aggregation of soluble proteins, but they do not induce the same acute mitochondrial and calcium dysregulation as oligomers [45]. The structural differences between oligomers and fibrils are significant; oligomers are often more dynamic and capable of interacting with cellular components in a way that leads to immediate cellular stress, while mature fibrils are more stable and less likely to engage in such interactions [45]. In summary, the differential toxicity of soluble oligomers versus mature fibrils is crucial in understanding myocardial injury mechanisms. Soluble oligomers are associated with acute mitochondrial dysfunction and calcium dysregulation, leading to significant cellular injury, while mature fibrils, although toxic, may exert their effects through different, less immediate pathways. This distinction is vital for developing therapeutic strategies aimed at mitigating the effects of protein aggregation-related diseases.

### *C. Cardiac Dysfunction*

Amyloid fibril deposition causes tissue damage, cellular damage, and ultimately organ malfunction (Figure 2). It appears there is a predominance of diffuse, peri-cellular, endocardial, arterial or arteriolar deposits in AL amyloidosis and nodular deposits in TTR amyloidosis, although the types of CA cannot be separated based on patterns of deposition. Large amyloid deposits in the myocardium's extracellular space cause loss of normal tissue architecture and function in both ATTR-CA and AL. They also cause progressive thickening and stiffening of the biventricular wall without ventricular dilatation to compensate, which results in a restrictive myopathy and low cardiac output. Isolated diastolic failure with normal systolic function is the early hallmark of the disease; however, as it advances, restrictive physiology becomes evident.




Fig 2 Mechanisms of Cardiac Failure in Cardiac Amyloidosis Caused by Immunoglobulin Light Chain (AL) and Transthyretin (TTR).

Small soluble monomers and oligomers are very toxic and are thought to be a primary factor in tissue and cell toxicity, in addition to the mechanical issues caused by amyloid fibril deposition. Differences in cardiac dysfunction, myocardial amyloid fibril load, and the more aggressive disease trajectory in patients with AL compared to ATTR-CA have been attributed to the direct toxic action of circulating light chains in AL amyloidosis.

Remarkably, light chain proteotoxicity as well as amyloid accumulation show distinct organ tropism. Cardiomyocytes' cellular redox status is altered by prefibrillar cardiotropic light chains, resulting in an increase in intracellular reactive oxygen species, oxidative stress, and death. Cardiomyocyte contractility and relaxation are directly hampered by the oxidant stress that the light chains impose, and this is accompanied by changes in intracellular calcium handling. By raising oxidative stress and apoptosis, p38 MAPK (mitogen-activated protein kinase) activation is one of the molecular pathways causing cardiotoxicity. Additionally, this route facilitates the transcription of brain natriuretic peptide (BNP), hence bolstering the correlation between elevated levels of BNP and enhanced MAPK activation, as well as cardiotoxic light chain effects.

According to clinical prognostic data, patients with AL amyloidosis have varying degrees of circulating light chain abnormalities, which is correlated with elevated cardiac biomarkers. Even if amyloid deposition in the myocardium remains same, chemotherapy-induced decreases in circulating amyloidogenic FLC concentrations translate into BNP reductions.

An increasing amount of research in TTR amyloidosis points to tissue dysfunction as a precursor to TTR fibril deposition and suggests that prefibrillar proteins in circulation are harmful. By interacting with membrane proteins and cholesterol, TTR monomers and oligomeric intermediates smaller than 100 kDa, but not large aggregates or amyloid fibrils, cause cytotoxicity in vitro. Cleavage of caspase 3/7 and the production of superoxide trigger apoptotic processes. It is yet unclear, nevertheless, how these short-term in vitro results relate to disease symptoms over the course of months or years [38].

*D. Sign and Symptoms*




Fig 3 Flowchart Illustrating the Categorization of Symptoms Associated with Various Conditions, Including Heart Failure, Arrhythmias, Chest Pain, Carpal Tunnel Syndrome, and Autonomic Dysfunction, Along with their Specific Manifestations.

*E. Diagnosis*

Recent advancements in imaging techniques for detecting transthyretin amyloid cardiomyopathy (ATTR-CM) have significantly enhanced diagnostic capabilities, particularly through the development of specialized PET tracers and the integration of artificial intelligence (AI) and machine learning (ML) methodologies. These innovations facilitate early detection and improved patient outcomes.

*F. Advancements in Imaging Techniques*

Positron Emission Tomography (PET) imaging has emerged as a pivotal tool in the diagnosis of amyloid diseases, including ATTR-CM. The introduction of specific PET tracers, such as ^18F-florbetapir and ^11C-Pittsburgh compound B (PiB), has enabled the in vivo visualization of amyloid deposits [46,47]. These tracers bind selectively to amyloid fibrils, allowing for the assessment of amyloid burden in the heart and other organs. Recent studies have demonstrated that PET imaging can differentiate between various types of amyloid deposits, providing critical information for clinical decision-making [48,47]. For instance, technetium-99m pyrophosphate (Tc-99m PYP) scintigraphy has shown high sensitivity for diagnosing ATTR-CM, outperforming other imaging modalities in certain contexts [48,49]. Moreover, advanced imaging techniques such as cardiac magnetic resonance imaging (CMR) with T1 mapping have been integrated into clinical practice, offering additional insights into myocardial tissue characteristics and extracellular volume [50,51]. These imaging modalities, when combined with traditional echocardiography, enhance the diagnostic accuracy for ATTR-CM by revealing characteristic patterns such as reduced longitudinal strain and increased left ventricular wall thickness [52,53].

*G. Role of Artificial Intelligence and Machine Learning*

The integration of AI and ML into the diagnostic process for ATTR-CM represents a transformative approach to early detection. Machine learning algorithms can analyze large datasets, including echocardiographic and electrocardiographic data, to identify patterns indicative of ATTR-CM [54,52]. For example, AI models have been developed to extract features from echocardiographic images, such as reduced global longitudinal strain and specific diastolic dysfunction patterns, which are critical for diagnosing cardiac amyloidosis [52,55]. These models can operate autonomously, pulling data from electronic health records (EHR) to flag patients at risk for ATTR-CM, thereby facilitating timely intervention [54]. Furthermore, deep learning techniques have been employed to harmonize PET imaging data across different tracers, improving the consistency and reliability of amyloid imaging interpretations [47]. This harmonization is crucial given the variability in tracer uptake and the need for standardized assessment protocols in clinical settings. In summary, the advancements in imaging techniques, particularly the development of specialized PET tracers and the application of AI and ML, are revolutionizing the early detection and diagnosis of ATTR-CM. These technologies not only enhance the accuracy of diagnosis but also pave the way for personalized treatment strategies, ultimately improving patient outcomes in this challenging condition.

*H. Pathways for the diagnosis*

Diagnostic procedures can be either non-invasive or invasive. First, a monoclonal protein screen should be performed as part of the cardiac amyloidosis diagnostic strategy (Figure 4) to determine whether there is evidence supporting AL-CM and/or a plasma cell disease. Heart uptake compatible with ATTR-CM (grade 2 or 3 uptake) may be seen in more than 10% to 30% of patients with AL-CM, despite the fact that "bone" scintigraphy has become a key component of non-invasive ET-CM diagnosis. Therefore, based on the existence or lack of a monoclonal protein, it is essential to select the proper diagnostic pathway. Separating ATTR-CM from AL-CM using a scintigraphy scan is neither acceptable nor valid.




Fig 4 This Image Shows a Diagnostic Flowchart for Evaluating Suspected Cardiac Amyloidosis, Particularly AL (Light Chain) Amyloidosis and ATTR (Transthyretin) Amyloidosis [11].

*I. Risk Factors*

Table 2. Table Summarizing Key Risk Factors for Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Including Age, Gender, Ethnicity, and Family History, with Descriptions Highlighting their Relevance and References for Further Context.

| Risk Factor | Description | Reference |
|---|---|---|
| Age | Older individuals are primarily affected by ATTR-CM, particularly in the case of wild-type ATTR (wtATTR). This form, often called senile systemic amyloidosis, typically affects men over the age of 60. | [56,57] |
| Gender | Men are more vulnerable than women, especially to wtATTR. This male predominance is likely due to differences in amyloid deposition patterns and sex-linked genetic factors. | [56,57] |
| Ethnicity | African or African-American ancestry is a significant risk factor for hereditary ATTR (hATTR). This population commonly carries a mutation (V122I) in the TTR gene, increasing the likelihood of developing ATTR-CM. | [56,57] |
| Family History | ATTR amyloidosis has an autosomal dominant inheritance pattern. A positive family history of the disorder increases the risk of developing hereditary ATTR (hATTR). | [56,57] |

*J. Epidemiology and Genetic Diversity*

Recent global epidemiological data has shed light on the regional variations in the prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM), particularly focusing on specific mutations such as Val122Ile. This mutation is notably prevalent in certain populations, especially among individuals of African descent, and has significant implications for the understanding and management of ATTR-CM.

*K. Regional Variations in Prevalence*

The Val122Ile mutation, which is associated with hereditary ATTR (hATTR), has been identified as a major contributor to the prevalence of ATTR-CM in specific regions. In the United States, it is estimated that approximately 3-4% of the African American population carries this mutation, making it one of the most common hereditary mutations linked to cardiac amyloidosis in this demographic [58,59]. Studies have shown that individuals with the Val122Ile mutation typically develop ATTR-CM later in life, often presenting with symptoms after the age of 60 [58,60]. This mutation is particularly significant in areas with high concentrations of African ancestry, where the penetrance of the mutation can vary widely, from 7% to as high as 100% depending on the diagnostic methods used [58]. In continental Western Europe, particularly in France, recent studies have indicated that about 5% of patients with a hypertrophic cardiomyopathy phenotype over the age of 63 were found to have ATTR-CM, with the Val122Ile mutation being the most common variant in this cohort [61]. This highlights the mutation's role in the European population, although it is less prevalent than in African American populations.

*L. Global Insights from Epidemiological Studies*

A multicenter study examining the association of the Val122Ile variant with heart failure among individuals of African or Hispanic/Latino ancestry revealed that this mutation is significantly more common in individuals of West African descent [62]. The study emphasized that the prevalence of the mutation and its clinical manifestations can differ markedly based on geographic and ethnic backgrounds, underscoring the importance of targeted screening in high-risk populations. In Japan, studies have indicated a lower prevalence of hereditary forms of ATTR-CM, with the Val122Ile mutation being rare. Instead, wild-type ATTR (wtATTR) is more commonly observed in older adults, particularly those presenting with heart failure with preserved ejection fraction [63]. This contrasts with findings from the United States, where hereditary forms are more frequently diagnosed.

*M. Implications for Diagnosis and Management*

The regional variations in the prevalence of ATTR-CM and specific mutations like Val122Ile have important implications for clinical practice. In areas with a high prevalence of the Val122Ile mutation, there is a pressing need for increased awareness and screening for ATTR-CM, particularly among older adults presenting with heart failure symptoms. The identification of this mutation can facilitate early diagnosis and timely intervention, which is crucial for improving patient outcomes [64].Moreover, the understanding of these epidemiological trends can inform healthcare policies and resource allocation, ensuring that populations at higher risk receive appropriate diagnostic and therapeutic options. As the global awareness of ATTR-CM continues to grow, ongoing research and surveillance will be essential to further elucidate the epidemiology of this condition and enhance management strategies tailored to specific populations. In summary, global epidemiological data reveals significant regional variations in the prevalence of ATTR-CM, particularly concerning the Val122Ile mutation. This mutation is most prevalent in African American populations and has implications for the diagnosis and management of the disease, highlighting the need for targeted screening and awareness in high-risk groups.

The underdiagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) in low-resource settings presents significant challenges, particularly given the increasing recognition of the disease's prevalence and its associated mortality rates. This underdiagnosis can lead to delayed treatment, worsening patient outcomes, and increased healthcare costs. Understanding the implications

of this issue and exploring strategies to improve diagnostic rates are crucial for enhancing patient care.

*N. Implications of Underdiagnosis in Low-Resource Settings*

Table 3. This Table Outlines the Critical Consequences of Underdiagnosing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and Highlights Strategic Approaches to Enhance Early Diagnosis.

| Aspect | Details |
|---|---|
| | **Implications of Underdiagnosis** |
| **Increased Mortality and Morbidity** | Underdiagnosis leads to untreated disease progression, causing higher mortality rates. For example, patients with the Val122Ile mutation, common among African Americans, often experience poor outcomes due to late diagnosis [65,66]. |
| **Healthcare Disparities** | Marginalized populations face more pronounced underdiagnosis, leading to disparities in outcomes. Black men, for instance, have high ATTR-CM mortality but face barriers to timely care, emphasizing the need for targeted interventions [65]. |
| **Economic Burden** | Delayed diagnosis increases healthcare costs due to complications, hospitalizations, and long-term care needs, straining limited resources in low-resource settings [67]. |
| | **Strategies to Improve Diagnostic Rates** |
| **Education and Training** | Educating healthcare providers on clinical presentation, risk factors, and diagnostic criteria enhances early recognition, especially in regions with high mutation rates like Val122Ile [66,75]. |
| **Implementation of Screening Programs** | Screening high-risk populations for mutations like Val122Ile facilitates early detection. Integrating these programs into routine healthcare can benefit areas with high hereditary ATTR prevalence [69]. |
| **Utilization of Advanced Imaging Techniques** | Incorporating cardiac MRI and echocardiography into clinical practice improves diagnostic accuracy. These imaging modalities detect characteristic ATTR-CM changes, such as increased left ventricular wall thickness [70,71] |
| **Collaboration with Specialized Centers** | Partnerships with specialized centers provide access to expertise and resources. Telemedicine and remote consultations bridge gaps in knowledge and facilitate timely referrals [72,73]. |
| **Community Awareness Campaigns** | Public health campaigns educate communities on ATTR-CM signs and symptoms, encouraging early medical attention and improving outcomes [74,75]. |

**Implications of underdiagnosis** include increased mortality and morbidity due to disease progression, healthcare disparities that disproportionately affect marginalized populations, and the economic burden stemming from delayed treatment and higher healthcare costs. **Strategies to improve diagnostic rates** focus on education, targeted screening, advanced imaging, collaboration with specialized centers, community outreach, genetic counseling, and the use of digital health tools to ensure timely and accurate identification of at-risk individuals. This comprehensive approach aims to address both systemic barriers and clinical challenges, improving patient outcomes and reducing healthcare inequities.

*O. Treatment options:*

Table 4. Categorization of Treatment Options for ATTR-CM, Including Pharmacological Therapies, Gene Silencing Techniques, Heart Failure Management, Cardiac Devices, Liver Transplantation, and Investigational Approaches, with Descriptions of their Mechanisms and Clinical Applications.

| Category | Therapy/Intervention | Description | References |
|---|---|---|---|
| **1.TTR Stabilizers** | **Tafamidis** | First-line therapy for wild-type and inherited ATTR-CM. Stabilizes transthyretin (TTR) and prevents amyloid fibril formation. Reduces cardiovascular hospitalizations and mortality. | [9] |
| | **Diflunisal** | Originally an NSAID, stabilizes TTR. Demonstrates modest benefits in slowing disease progression but is less widely used compared to tafamidis. | [76] |
| **2.Gene Silencing Therapies** | **Patisiran** | RNA interference (RNAi) therapy targeting hepatic synthesis of wild-type and mutant TTR. Primarily used for hereditary ATTR polyneuropathy but may benefit cardiac involvement. | [9] |
| | **Inotersen** | Antisense oligonucleotide that reduces TTR synthesis. Used for combined cardiac and neuropathic symptoms in hereditary ATTR. Approved for hereditary ATTR polyneuropathy. | [76] |

| | | | |
|---|---|---|---|
| **3.Heart Failure Management** | **Diuretics** | Treats fluid overload symptoms like peripheral edema and dyspnea. Commonly uses loop diuretics such as furosemide. | [9] |
| | **Beta-blockers and ACE Inhibitors** | Administered cautiously due to diastolic dysfunction and low blood pressure in ATTR-CM. Can be used to treat atrial fibrillation and heart failure symptoms. | [76] |
| | **Anticoagulation** | Recommended to mitigate thromboembolism risk, especially in patients with atrial fibrillation. | [9] |
| **4.Cardiac Devices** | **Pacemakers** | Implanted to manage conduction anomalies like atrioventricular (AV) block and bradycardia common in ATTR-CM. | [76] |
| | **ICDs** | Implantable cardioverter-defibrillators (ICDs) may be used for patients with high-risk arrhythmias, despite sudden cardiac death being less common in ATTR-CM. | [9] |
| **5.Liver Transplantation** | **Liver Transplant** | Replaces the source of mutant TTR protein in hereditary ATTR amyloidosis, halting disease progression. Less common due to advances in pharmaceutical therapies. | [76] |
| **6.Investigational Therapies** | **CRISPR-Cas9** | Gene-editing technology in experimental stages aimed at correcting TTR gene mutations causing hereditary ATTR-CM. | [76] |
| | **New TTR Silencers and Fibril Disruptors** | Emerging therapies in clinical trials to dissolve existing amyloid fibrils or further reduce TTR synthesis. | [9] |

*P. Prognosis and Disease Progression*

Recent insights into prognostic biomarkers for transthyretin amyloid cardiomyopathy (ATTR-CM) have significantly advanced the understanding of disease progression and patient outcomes. Key developments include the evaluation of serum amyloid P-component (SAP) levels and novel imaging metrics, particularly the quantification of extracellular volume fraction (ECV) using cardiac magnetic resonance imaging (CMR).

*Q. Serum Amyloid P-Component Levels*

Serum amyloid P-component (SAP) has emerged as a potential biomarker for monitoring amyloid load and disease progression in ATTR-CM. Elevated levels of SAP have been associated with increased amyloid burden and worse clinical outcomes. Recent studies suggest that changes in SAP levels may correlate with disease severity and response to treatment, providing valuable prognostic information [77]. For instance, monitoring SAP levels alongside other cardiac biomarkers, such as NT-proBNP, can enhance the assessment of cardiac involvement and guide therapeutic decisions [78,79].

*R. Extracellular Volume Fraction Quantification Using Cardiac MRI*

The quantification of extracellular volume fraction (ECV) using cardiac MRI has gained prominence as a prognostic tool in ATTR-CM. ECV quantification allows for the assessment of myocardial fibrosis and amyloid deposition, which are critical determinants of cardiac function and prognosis. Studies have shown that increased ECV is associated with higher amyloid load and correlates with other markers of disease status, including cardiac biomarkers and imaging findings [80]. For example, ECV measurements have been linked to mortality in ATTR-CM patients, highlighting their potential as a prognostic indicator [80,81]. In addition to ECV, other imaging metrics derived from CMR, such as native T1 mapping and late gadolinium enhancement (LGE), have been shown to provide complementary information regarding myocardial involvement in ATTR-CM. These imaging techniques can identify structural changes in the myocardium and help stratify patients based on their risk of adverse outcomes [81,82]. The integration of these imaging modalities into clinical practice enhances the ability to monitor disease progression and treatment response, particularly in patients receiving therapies like tafamidis [83,84].

*S. Clinical Implications and Future Directions*

The combination of serum biomarkers and advanced imaging techniques offers a comprehensive approach to assessing ATTR-CM. By integrating SAP levels and ECV quantification, clinicians can better stratify patients according to their risk profiles and tailor treatment strategies accordingly. Furthermore, ongoing research aims to validate these biomarkers in larger cohorts and explore their utility in clinical trials, which may lead to more standardized protocols for monitoring and managing ATTR-CM [77,85]. In conclusion, recent advancements in understanding prognostic biomarkers for ATTR-CM, particularly changes in serum amyloid P-component levels and novel imaging metrics such as extracellular volume fraction quantification using cardiac MRI, provide valuable insights into disease progression and patient management. These developments hold promise for improving clinical outcomes and guiding therapeutic interventions in this challenging condition.

*T. Patient Perspectives and Support*

Recent studies on patient-reported outcomes (PROs) have provided valuable insights into enhancing the assessment of treatment efficacy in patient-centered care. By focusing on the experiences, preferences, and satisfaction of patients, these studies contribute to a more holistic understanding of treatment effectiveness beyond traditional clinical metrics. Here, we explore how PROs can improve treatment assessment and the implications for patient-centered care.

*U. Enhancing Treatment Efficacy Assessment through PROs*

Table 5. This table highlights the important role of **Patient-Reported Outcomes (PROs)** in enhancing healthcare delivery. By integrating PROs into clinical practice, healthcare providers can gain a more comprehensive understanding of patients' experiences, leading to improved decision-making, treatment personalization, and overall care quality.

| Key Aspect | Description | References |
|---|---|---|
| 1. Incorporating Patient Perspectives | PROs (Patient-Reported Outcomes) capture patients' subjective experiences regarding their health, treatment effects, and quality of life. This information helps understand how treatments affect daily lives and overall well-being. Integrating PROs into clinical practice improves communication and fosters a collaborative care approach, enabling treatments to be tailored to individual needs for better efficacy. | [86,87] |
| 2. Facilitating Shared Decision-Making | PROs support SDM by providing patients with relevant information about treatment options and outcomes. This empowers patients to express preferences and values, leading to personalized treatment choices. Active patient involvement enhances satisfaction with care and adherence to treatment plans, improving overall strategy effectiveness. | [88,89] |
| 3. Monitoring Treatment Outcomes | PROs are tools for tracking treatment outcomes over time. Regular assessments of patients' self-reported health status help clinicians detect changes indicating treatment success or adjustments. In chronic disease management, PROs related to symptoms, function, and quality of life guide interventions and responsive care adjustments. | [89,90,91,92] |
| 4. Identifying Areas for Improvement | PRO analysis identifies gaps in care and areas needing improvement. Patient satisfaction, closely tied to treatment outcomes, underscores the need to address patient concerns and preferences. Systematic PRO collection helps organizations identify trends and implement quality-improvement strategies. | [90,93,94,95] |
| 5. Supporting Health Equity | PROs highlight disparities in treatment experiences across diverse patient populations, such as by race, ethnicity, or socioeconomic status. Insights from PROs guide strategies to enhance access and care for underserved groups, reducing disparities and ensuring equitable, high-quality, patient-centered care. | [96] |

In conclusion, recent studies on patient-reported outcomes have underscored their importance in enhancing the assessment of treatment efficacy within patient-centered care. By incorporating patient perspectives, facilitating shared decision-making, monitoring treatment outcomes, identifying areas for improvement, and supporting health equity, PROs contribute to a more comprehensive understanding of treatment effectiveness. As healthcare continues to evolve towards more patient-centered models, the integration of PROs into clinical practice will be essential for improving patient outcomes and overall satisfaction with care.

*V. The Multifaceted Impact of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) on Caregivers*

The impact of transthyretin amyloid cardiomyopathy (ATTR-CM) on caregivers is profound and multifaceted, affecting their emotional, psychological, and physical well-being. Recent studies and testimonials provide critical insights into the challenges faced by caregivers of patients with ATTR-CM, highlighting the need for supportive measures and resources.

*W. Emotional and Psychological Burden*

Caregivers of patients with ATTR-CM often experience significant emotional distress. A study indicated that 44% of caregivers experienced anxiety and 39% reported depression [97]. This emotional burden is compounded by the stress of managing complex care needs, which can lead to feelings of helplessness and isolation. Testimonials from caregivers reveal that the uncertainty surrounding the progression of the disease and the potential for worsening symptoms contribute to chronic stress and emotional fatigue [98,99]. For instance, caregivers have expressed feelings of fear and hopelessness as they navigate the challenges of supporting a loved one with a progressive and often debilitating condition. These sentiments are echoed in focus group discussions, where caregivers shared their struggles with balancing caregiving responsibilities alongside their personal lives, leading to increased stress and diminished quality of life [98].

*X. Impact on Daily Life and Relationships*

The caregiving role can significantly alter daily routines and relationships. Caregivers often find themselves dedicating substantial time and energy to assist with activities of daily living, managing medications, and coordinating medical appointments. This can lead to disruptions in their own work and social lives, resulting in feelings of resentment and frustration [97]. The burden of caregiving can strain relationships, not only between caregivers and patients but also among family members, as the dynamics shift to accommodate the needs of the patient [100]. A study highlighted that approximately 35% of caregivers reported a mild to moderate burden of care, indicating that many caregivers struggle to cope with the demands placed upon them [97]. This burden can lead to caregiver burnout, which is characterized by emotional

exhaustion, reduced personal accomplishment, and depersonalization towards the patient [100].

*Y. Supportive Strategies and Recommendations*

Table 6 Strategy

| Strategy | Details |
|---|---|
| 1. Education and Training | Educating caregivers about ATTR-CM, its progression, and management strategies can empower them, reduce anxiety, and improve their ability to provide effective care [97]. |
| 2. Support Groups | Establishing support groups allows caregivers to share experiences and coping strategies, reducing feelings of isolation and providing emotional support [100]. |
| 3. Access to Mental Health Resources | Providing counseling and therapy helps caregivers address emotional and psychological needs, offering coping strategies for managing stress and anxiety [97]. |
| 4. Respite Care Services | Respite care services give caregivers time to rest and care for their own health, preventing burnout and improving the quality of care [100]. |
| 5. Involvement in Care Planning | Encouraging caregiver participation in care planning and decision-making fosters a sense of involvement and enhances communication with healthcare providers, improving outcomes [99]. |

## VI. RESEARCH AND FUTURE DIRECTION:

Preventive strategies for transthyretin amyloid cardiomyopathy (ATTR-CM) can be significantly enhanced through the identification of at-risk populations via genetic screening and the implementation of early interventions aimed at slowing disease progression. These strategies are crucial given the often insidious nature of ATTR-CM, which can lead to severe morbidity and mortality if not diagnosed and treated promptly. Genetic screening plays a pivotal role in identifying individuals at risk for hereditary forms of ATTR-CM, particularly those with known transthyretin (TTR) gene mutations. Genetic counseling and testing are essential for assessing familial causes of ATTR-CM, which can facilitate earlier diagnosis and treatment for affected family members [101]. Moreover, certain demographic factors, such as being Black or female, have been associated with a higher risk of variant ATTR-CM, underscoring the need for targeted screening in these populations [101,102]. The incorporation of genetic testing into routine clinical practice can help differentiate between wild-type and variant forms of the disease, allowing for tailored management strategies [103,104]. In addition to genetic screening, the development of risk assessment tools, such as the ATTR-CM score, can enhance the identification of high-risk patients, particularly those with heart failure with preserved ejection fraction (HFpEF) [55,105]. This score integrates clinical and echocardiographic variables to stratify patients based on their likelihood of having ATTR-CM, thereby guiding further diagnostic testing and early intervention [55]. The systematic application of such scoring systems in clinical settings may improve the cost-effectiveness of screening efforts and facilitate timely referrals for specialized care [55,105]. Early intervention is critical in managing ATTR-CM, as treatments like tafamidis have demonstrated efficacy in slowing disease progression, particularly when administered in the early stages of the disease [105,107]. The ATTR-ACT trial highlighted that initiating treatment with tafamidis can significantly improve survival and quality of life for patients with ATTR-CM [107]. Furthermore, the identification of clinical red flags, such as unexplained heart failure symptoms or carpal tunnel syndrome, can prompt earlier diagnostic evaluations and therapeutic interventions [108,109]. The integration of non-invasive diagnostic strategies, including bone scintigraphy and advanced imaging techniques, can also facilitate early detection of ATTR-CM. These methods have been shown to differentiate ATTR-CM from other forms of cardiac amyloidosis, thus allowing for more accurate diagnoses and timely treatment initiation [110,111]. In conclusion, expanding preventive strategies for ATTR-CM through genetic screening and early intervention can significantly enhance patient outcomes. By identifying at-risk populations and implementing targeted screening protocols, healthcare providers can facilitate earlier diagnosis and treatment, ultimately slowing disease progression and improving the quality of life for patients with this challenging condition.

## VII. THERAPEUTICS AND EMERGING TREATMENT

*A. Advancements in the Therapeutic Landscape of Transthyretin Amyloidosis (ATTR)*

Recent developments in the treatment of transthyretin amyloidosis (ATTR) have focused on novel TTR stabilizers and fibril-disrupting agents, with significant findings emerging from clinical trials. These advancements aim to address the underlying pathophysiology of ATTR, which involves the misfolding and aggregation of TTR proteins, leading to amyloid fibril formation and subsequent organ damage.

### B. Novel TTR Stabilizers

Tafamidis, a first-in-class TTR stabilizer, has been a major breakthrough in the treatment of ATTR. It works by binding to the T4-binding sites of TTR, thereby stabilizing the tetrameric structure and preventing its dissociation into amyloidogenic monomers [112,113]. Clinical trials, such as the Phase 3 ATTR-ACT trial, demonstrated that tafamidis significantly slows the progression of cardiac and neurological symptoms in patients with ATTR, leading to improved survival rates [114,115]. The efficacy of tafamidis has established it as a standard treatment for both hereditary and wild-type ATTR amyloidosis. In addition to tafamidis, other small molecules have been investigated for their potential as TTR stabilizers. Diflunisal, a non-steroidal anti-inflammatory drug, has shown promise in stabilizing TTR and has been associated with survival

benefits comparable to tafamidis [116,117]. Furthermore, novel compounds such as AG10 have been developed, which exhibit enhanced binding affinity to TTR and demonstrate potent stabilizing effects in preclinical models [118]. These compounds are currently undergoing clinical evaluation to assess their safety and efficacy in human subjects.

*C. Fibril-Disrupting Agents*

In parallel with TTR stabilizers, research has also focused on fibril-disrupting agents that can dissolve existing amyloid deposits. Monoclonal antibodies targeting TTR fibrils have shown potential in preclinical studies, demonstrating the ability to reduce amyloid burden in tissues [117]. Additionally, agents like doxycycline and tauroursodeoxycholic acid are being explored for their fibril-disrupting properties, with early studies suggesting they may help in reducing amyloid deposits and improving cardiac function [117,119]. Recent studies have also highlighted the role of natural compounds, such as santalol isomers, which have been shown to inhibit TTR amyloidogenesis in model organisms like *Caenorhabditis elegans* [120]. These findings suggest that phytochemicals may offer a novel therapeutic avenue for managing ATTR.

*D. Clinical Trials and Future Directions*

The ongoing clinical trials for these novel agents are crucial for establishing their clinical utility. For instance, the APOLLO trial demonstrated that patisiran, a small interfering RNA (siRNA) therapeutic, significantly improved neuropathy symptoms in hereditary ATTR patients, and it is currently being evaluated for its effects on cardiac manifestations [121]. Similarly, inotersen, an antisense oligonucleotide, has shown promise in reducing TTR levels and improving quality of life in patients with hereditary ATTR [122]. In conclusion, the landscape of treatment for ATTR is rapidly evolving, with novel TTR stabilizers and fibril-disrupting agents showing promise in clinical trials. The combination of these therapeutic strategies may provide a comprehensive approach to managing ATTR, addressing both the stabilization of TTR and the reduction of amyloid burden in affected tissues.

*E. CRISPR/Cas9: A Revolutionary Approach to Treating Transthyretin Amyloid Cardiomyopathy (ATTR-CM*

Recent advancements in CRISPR/Cas9 gene editing technology have shown promising potential for treating transthyretin amyloid cardiomyopathy (ATTR-CM). This innovative approach aims to directly target and modify the TTR gene, which is responsible for producing the transthyretin protein implicated in amyloid fibril formation. The following discussion highlights the latest developments and findings from preclinical and initial clinical trials regarding CRISPR/Cas9 applications in ATTR-CM.

*F. Advancements in CRISPR/Cas9 for ATTR-CM*

One of the most notable advancements in CRISPR/Cas9 technology for ATTR-CM is the development of NTLA-2001, an intravenous CRISPR-based therapeutic designed to reduce TTR expression. In preclinical studies, NTLA-2001 demonstrated a remarkable ability to decrease TTR levels by up to 90% in primary human hepatocytes, indicating its potential efficacy in reducing amyloidogenic protein production [113]. This significant reduction in TTR expression is crucial, as it directly correlates with decreased amyloid deposition and subsequent organ damage. Initial clinical trials have begun to assess the safety and efficacy of NTLA-2001 in patients with ATTR amyloidosis. The early results from these trials have been encouraging, suggesting that a single administration of NTLA-2001 could potentially eradicate the source of the disease, offering a true curative approach for patients suffering from this progressive disorder [114]. The completed Phase I trial results are eagerly anticipated, as they will provide critical insights into the long-term effects and safety profile of this gene-editing strategy.

*G. Preclinical and Clinical Findings*

Preclinical studies have also explored the safety and specificity of CRISPR/Cas9 gene editing in the context of ATTR-CM. For instance, rigorous evaluations have been conducted to assess off-target effects, which are a common concern with gene-editing technologies. In studies utilizing primary human hepatocytes, researchers found no evidence of off-target editing at concentrations of NTLA-2001 that were significantly higher than therapeutic levels, suggesting a favorable safety profile for this approach [115]. This is crucial for advancing CRISPR/Cas9 therapies into clinical settings, as minimizing unintended genetic modifications is essential for patient safety. Moreover, the potential of CRISPR/Cas9 to provide a one-time treatment option for ATTR-CM patients is particularly appealing. Unlike traditional therapies that may require ongoing administration, CRISPR-based interventions could lead to sustained reductions in TTR levels, thereby addressing the root cause of the disease rather than merely managing symptoms [116]. This transformative potential is underscored by the ongoing Phase I trials, which aim to evaluate the long-term impact of CRISPR/Cas9 gene editing on TTR levels and clinical outcomes in affected individuals [114,116].

In summary, the advancements in CRISPR/Cas9 gene editing for ATTR-CM represent a significant leap forward in the quest for effective treatments for this challenging condition. The promising results from preclinical studies and initial clinical trials suggest that CRISPR-based therapies could offer a novel and potentially curative approach to managing ATTR amyloidosis. As research progresses, further studies will be essential to fully understand the long-term implications of gene editing in this context, including efficacy, safety, and the potential for broader applications in other forms of amyloidosis.

*H. Abbreviations*

**ATTR-CM** – Transthyretin Amyloid Cardiomyopathy
**TTR** – Transthyretin
**Tc-99m PYP** – Technetium-99m Pyrophosphate
**PET** – Positron Emission Tomography
**AI** – Artificial Intelligence
**ML** – Machine Learning
**SAP** – Serum Amyloid P-Component

**ECV** – Extracellular Volume Fraction
**EHR** – Electronic Health Records
**hATTR** – Hereditary Transthyretin Amyloidosis
**wtATTR** – Wild-type Transthyretin Amyloidosis
**NT-proBNP** – N-terminal pro B-type natriuretic peptide

## VIII. CONCLUSION

In our review of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), we highlight several promising advancements and future directions in the field. One of the most transformative approaches we discuss is the potential of CRISPR/Cas9 gene editing, which could offer a one-time treatment option that directly addresses the root cause of the disease by reducing TTR levels, rather than merely alleviating symptoms. Preclinical studies have shown encouraging results regarding the safety and specificity of CRISPR/Cas9, with no significant off-target effects observed at therapeutic levels. Ongoing Phase I trials are critical for assessing the long-term clinical impact of these therapies. We also emphasize the importance of incorporating patient-reported outcomes (PROs) into clinical practice, as they offer valuable insights into patients' experiences, preferences, and satisfaction, which can improve treatment efficacy assessments and facilitate personalized care. Furthermore, we explore advancements in biomarkers, such as serum amyloid P-component levels, and imaging techniques like extracellular volume fraction quantification through cardiac MRI, which are expected to enhance patient management and guide therapeutic decisions. We conclude by stressing the need for continued research to validate biomarkers in larger cohorts, enabling the development of standardized protocols for monitoring and managing ATTR-CM. Ultimately, we believe that these innovative therapies and patient-centered approaches hold significant promise in improving the management and treatment of ATTR-CM.

## REFERENCES

[1]. Picken, M. M., Herrera, G. A., & Dogan, A. (2015). *Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations*. Humana Press.
[2]. Conceição I, González-Duarte A, Obici L, et al. "Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy." J Peripher Nerv Syst. 2016;21(1):5-9. doi:10.1111/jns.12171.
[3]. Wilde, A. a. M., Semsarian, C., Márquez, M. F., Shamloo, A. S., Ackerman, M. J., Ashley, E. A., Sternick, E. B., Barajas-Martinez, H., Behr, E. R., Bezzina, C. R., Breckpot, J., Charron, P., Chockalingam, P., Crotti, L., Gollob, M. H., Lubitz, S., Makita, N., Ohno, S., Ortiz-Genga, M., . . . Deneke, T. (2022). European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. *EP Europace*, *24*(8), 1307–1367. https://doi.org/10.1093/europace/euac030
[4]. Pantoni, L., & Gorelick, P. B. (2014). Cerebral Small Vessel Disease. Cambridge University Press.
[5]. Quarta CC, Kruger JL, Falk RH. "Cardiac amyloidosis." Circulation. 2012;126(12). doi:10.1161/CIRCULATIONAHA.111.069195.
[6]. Abstract proceedings of the best case report contest 2022. Clinical Cases in Internal Medicine: Learning Through Practice (7th McMaster International Review Course in Internal Medicine, September 29–October 1, 2022, Kraków, Poland, hybrid course). (2022). *Polskie Archiwum Medycyny Wewnętrznej*, *132*(Special Issue 1). https://doi.org/10.20452/pamw.16376
[7]. Gillmore JD, Maurer MS, Falk RH, et al. "Nonbiopsy diagnosis of cardiac transthyretin amyloidosis." Circulation. 2016;133(24):2404-2412. doi:10.1161/CIRCULATIONAHA.116.021612.i8
[8]. Kristen, A.V., Dengler, T.J. and Katus, H.A. (2007) 'Suspected cardiac amyloidosis: Endomyocardial biopsy remains the diagnostic gold-standard', American Journal of Hematology, 82(4), pp. 328–328. doi:10.1002/ajh.20745.
[9]. Maurer MS, Schwartz JH, Gundapaneni B, et al. "Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy." N Engl J Med. 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689.
[10]. Crommelin, D. J. A., & Sindelar, R. D. (2002). *Pharmaceutical Biotechnology: Fundamentals and Applications, Second Edition*. CRC Press
[11]. Brito D, Albrecht FC, De Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P. World heart federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM). Global Heart. 2023;18(1).
[12]. Castano A, Narotsky DL, Hamid N, et al. "Wild-type transthyretin cardiac amyloidosis: Strategies to raise awareness and aid diagnosis." JACC Heart Fail. 2017;5(7):573-581. doi:10.1016/j.jchf.2017.05.001.
[13]. Sabuncuoğlu, S., Yalcinkaya, A., Zhou, X., Münch, G., Chang, D., Borrelli, E., Le, N., Gangwar, B., Kumar, S., Darokar, M., Čolak, E., Žorić, L., Mirković, M., Mirković, J., Dragojević, I., Mirić, D., Kisić, B., Nikolić, L., Barderas, M., . . . González-Hernández, J. C. (2022). Importance of Oxidative Stress and Antioxidant System in Health and Disease. In *Biochemistry*. https://doi.org/10.5772/intechopen.100949
[14]. Planté-Bordeneuve, V., & Kerschen, P. (2013). *Peripheral Nerve Disorders: Chapter 38. Transthyretin familial amyloid polyneuropathy*. Elsevier Inc. Chapters.
[15]. Gertz, M. A., & Rajkumar, S. V. (2010). *Amyloidosis: Diagnosis and Treatment*. Springer Science & Business Media.
[16]. Maas, C. (2009). The Mechanism of Activation of the Contact System and Fibrinolytic System. *Amyloid*, *16*(2), 111. https://doi.org/10.1080/13506120902879954

[17]. Jacobson DR, et al. "Transthyretin amyloidosis: Molecular mechanisms and clinical implications." *Blood Reviews*. 2020;44:100678. doi:10.1016/j.blre.2020.100678.
[18]. Benson MD. "The molecular basis of transthyretin amyloidosis." *Clinical Chemistry and Laboratory Medicine*. 2017;55(5):779-788. doi:10.1515/cclm-2016-0792.
[19]. Liu H, et al. "Transthyretin and the pathogenesis of amyloidosis." *Journal of Molecular Medicine*. 2014;92(1):23-35. doi:10.1007/s00109-013-1022-4.
[20]. Brodsky B, et al. "Amyloid fibril formation: A view from the bench." *Nature Reviews Molecular Cell Biology*. 2009;10(9):653-664. doi:10.1038/nrm2748.
[21]. Pensalfini, A., Albay, R., Rasool, S., Wu, J. W., Hatami, A., Arai, H., Margol, L., Milton, S., Poon, W. W., Corrada, M. M., Kawas, C. H., & Glabe, C. G. (2014). Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. *Neurobiology of Disease*, *71*, 53–61. https://doi.org/10.1016/j.nbd.2014.07.011
[22]. Wang, H., Sun, M., Li, W., Liu, X., Zhu, M., & Qin, H. (2023). Biomarkers associated with the pathogenesis of Alzheimer's disease. *Frontiers in Cellular Neuroscience*, *17*. https://doi.org/10.3389/fncel.2023.1279046
[23]. Kim, E. S., Bruinooge, S. S., Roberts, S., Ison, G., Lin, N. U., Gore, L., Uldrick, T. S., Lichtman, S. M., Roach, N., Beaver, J. A., Sridhara, R., Hesketh, P. J., Denicoff, A. M., Garrett-Mayer, E., Rubin, E., Multani, P., Prowell, T. M., Schenkel, C., Kozak, M., . . . Schilsky, R. L. (2017). Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. *Journal of Clinical Oncology*, *35*(33), 3737–3744. https://doi.org/10.1200/jco.2017.73.7916
[24]. Maurer, M. S., Elliott, P., Merlini, G., et al. (2019). Cardiac amyloidosis: Updates in pathophysiology, diagnosis, and treatment strategies. *Journal of the American College of Cardiology*, 73(22), 2871–2885. https://doi.org/10.1016/j.jacc.2019.04.003
[25]. Mattsson, G., & Magnusson, P. (2021). *Cardiomyopathy: Disease of the Heart Muscle*.
[26]. Connors, L. H., Mintz, L. J., & Weiss, M. (2016). The classification of cardiac amyloidosis. *Journal of the American College of Cardiology*, 67(19), 2300–2311. https://doi.org/10.1016/j.jacc.2016.02.060
[27]. Ruberg, F. L., & Berk, J. L. (2012). Transthyretin (TTR) cardiac amyloidosis: An infiltrative cardiomyopathy with treatment options. *Journal of the American College of Cardiology*, 66(1), 83–99. https://doi.org/10.1016/j.jacc.2012.06.024
[28]. Böhles, H., & Sewell, A. C. (2004). *Metabolic Cardiomyopathy*. CRC Press.
[29]. Cao, Q., Anderson, D., Liang, W., Chou, J., & Saelices, L. (2020). The inhibition of cellular toxicity of amyloid-β by dissociated transthyretin. Journal of Biological Chemistry, 295(41), 14015-14024. https://doi.org/10.1074/jbc.ra120.013440
[30]. Cioffi, C., Raja, A., Muthuraman, P., Jayaraman, A., Jayakumar, S., Váradi, A., … & Petrukhin, K. (2021). Identification of transthyretin tetramer kinetic stabilizers that are capable of inhibiting the retinol-dependent retinol binding protein 4-transthyretin interaction: potential novel therapeutics for macular degeneration, transthyretin amyloidosis, and their common age-related comorbidities. Journal of Medicinal Chemistry, 64(13), 9010-9041. https://doi.org/10.1021/acs.jmedchem.1c00099
[31]. Ferreira, N., Pereira-Henriques, A., & Almeida, M. (2015). Transthyretin chemical chaperoning by flavonoids: structure–activity insights towards the design of potent amyloidosis inhibitors. Biochemistry and Biophysics Reports, 3, 123-133. https://doi.org/10.1016/j.bbrep.2015.07.019
[32]. Ferreira, N., Saraiva, M., & Almeida, M. (2011). Natural polyphenols inhibit different steps of the process of transthyretin (ttr) amyloid fibril formation. Febs Letters, 585(15), 2424-2430. https://doi.org/10.1016/j.febslet.2011.06.030
[33]. Greene, M., Klimtchuk, E., Seldin, D., Berk, J., & Connors, L. (2014). Cooperative stabilization of transthyretin by clusterin and diflunisal. Biochemistry, 54(2), 268-278. https://doi.org/10.1021/bi5011249
[34]. Jesus, C., Almeida, Z., Vaz, D., Faria, T., & Brito, R. (2016). A new folding kinetic mechanism for human transthyretin and the influence of the amyloidogenic v30m mutation. International Journal of Molecular Sciences, 17(9), 1428. https://doi.org/10.3390/ijms17091428
[35]. Sun, X. (2023). Probing the dissociation pathway of a kinetically labile transthyretin mutant. Journal of the American Chemical Society, 146(1), 532-542. https://doi.org/10.1021/jacs.3c10083
[36]. Sun, X., Ferguson, J., Leach, B., Stanfield, R., Dyson, H., & Wright, P. (2023). Probing the dissociation pathway of a kinetically labile transthyretin mutant.. https://doi.org/10.1101/2023.06.21.545798
[37]. Yokoyama, T., Kosaka, Y., & Mizuguchi, M. (2014). Crystal structures of human transthyretin complexed with glabridin. Journal of Medicinal Chemistry, 57(3), 1090-1096. https://doi.org/10.1021/jm401832j
[38]. Patel KP, Scully PR, Saberwal B, Sinha A, Yap-Sanderson JJ, Cheasty E, Mullen M, Menezes LJ, Moon JC, Pugliese F, Klotz E. Regional distribution of extracellular volume quantified by cardiac CT in aortic stenosis: insights into disease mechanisms and impact on outcomes. Circulation: Cardiovascular Imaging. 2024 May;17(5):e015996.
[39]. Silva-Álvarez, C., Arrázola, M., Godoy, J., Ordenes, D., & Inestrosa, N. (2013). Canonical wnt signaling protects hippocampal neurons from aβ oligomers: role of non-canonical wnt-5a/ca2+ in mitochondrial dynamics. Frontiers in Cellular Neuroscience, 7. https://doi.org/10.3389/fncel.2013.00097

[40]. Rui, Y. and Zheng, J. (2016). Amyloid β oligomers elicit mitochondrial transport defects and fragmentation in a time-dependent and pathway-specific manner. Molecular Brain, 9(1). https://doi.org/10.1186/s13041-016-0261-z

[41]. Luth, E., Stavrovskaya, I., Bartels, T., Kristal, B., & Selkoe, D. (2014). Soluble, prefibrillar α-synuclein oligomers promote complex i-dependent, ca2+-induced mitochondrial dysfunction. Journal of Biological Chemistry, 289(31), 21490-21507. https://doi.org/10.1074/jbc.m113.545749

[42]. Farrugia, M., Caruana, M., Ghio, S., Camilleri, A., Farrugia, C., Cauchi, R., … & Vassallo, N. (2020). Toxic oligomers of the amyloidogenic hypf-n protein form pores in mitochondrial membranes. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-74841-z

[43]. Alberdi, E., Sánchez-Gómez, M., Cavaliere, F., Pérez-Samartín, A., Zugaza, J., Trullás, R., … & Matute, C. (2010). Amyloid β oligomers induce ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium, 47(3), 264-272. https://doi.org/10.1016/j.ceca.2009.12.010

[44]. Yang, Z., Subati, T., Kim, K., Murphy, M., Dougherty, O., Christopher, I., … & Murray, K. (2022). Natriuretic peptide oligomers cause proarrhythmic metabolic and electrophysiological effects in atrial myocytes. Circulation Arrhythmia and Electrophysiology, 15(3). https://doi.org/10.1161/circep.121.010636

[45]. Verma, M., Vats, A., & Taneja, V. (2015). Toxic species in amyloid disorders: oligomers or mature fibrils. Annals of Indian Academy of Neurology, 18(2), 138. https://doi.org/10.4103/0972-2327.144284

[46]. Su, Y., Flores, S., Wang, G., Hornbeck, R. C., Speidel, B., Joseph-Mathurin, N., … & Benzinger, T. L. (2019). Comparison of pittsburgh compound b and florbetapir in cross-sectional and longitudinal studies. Alzheimer's &Amp; Dementia: Diagnosis, Assessment &Amp; Disease Monitoring, 11(1), 180-190. https://doi.org/10.1016/j.dadm.2018.12.008

[47]. Shah, J., Gao, F., Li, B., Ghisays, V., Luo, J., Chen, Y., … & Wu, T. (2022). Deep residual inception encoder-decoder network for amyloid pet harmonization. Alzheimer S & Dementia, 18(12), 2448-2457. https://doi.org/10.1002/alz.12564

[48]. Chiou, A., Aman, E., & Kesarwani, M. (2020). A case report of an infiltrative cardiomyopathy in everyday practice: a specific cause that cannot be missed in the elderly. European Heart Journal - Case Reports, 4(6), 1-6. https://doi.org/10.1093/ehjcr/ytaa382

[49]. Treglia, G., Glaudemans, A., Bertagna, F., Hazenberg, B., Erba, P., Giubbini, R., … & Slart, R. (2018). Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 45(11), 1945-1955. https://doi.org/10.1007/s00259-018-4013-4

[50]. Alexander, K., Orav, J., Singh, A., Jacob, S., Menon, A., Padera, R., … & Dorbala, S. (2018). Geographic disparities in reported us amyloidosis mortality from 1979 to 2015. Jama Cardiology, 3(9), 865. https://doi.org/10.1001/jamacardio.2018.2093

[51]. García-Pavía, P., Rapezzi, C., Adler, Y., Arad, M., Basso, C., Brucato, A., … & Linhart, A. (2021). Diagnosis and treatment of cardiac amyloidosis: a position statement of the esc working group on myocardial and pericardial diseases. European Heart Journal, 42(16), 1554-1568. https://doi.org/10.1093/eurheartj/ehab072

[52]. Mitchell, J., Lenihan, D., Reed, C., Huda, A., Nolen, K., Bruno, M., … & Kannampallil, T. (2022). Implementing a machine-learning-adapted algorithm to identify possible transthyretin amyloid cardiomyopathy at an academic medical center. Clinical Medicine Insights Cardiology, 16. https://doi.org/10.1177/11795468221133608

[53]. 53.Mircsof, D. (2020). Diagnosis of amyloidosis: a survey of current awareness and clinical challenges among cardiologists in switzerland. Cardiology and Therapy, 9(1), 127-138. https://doi.org/10.1007/s40119-019-00160-8

[54]. Huda, A., Castaño, A., Niyogi, A., Schumacher, J., Stewart, M., Bruno, M., … & Shah, S. (2021). A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-22876-9

[55]. Lau, A. (2023). Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (attr-cm) in patients with heart failure with preserved ejection fraction (hfpef) in united states.. https://doi.org/10.1101/2023.08.14.23294100

[56]. Maurer MS, Elliott P, Comenzo R, et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. *Circulation: Heart Failure*. 2017.

[57]. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. *Muscle & Nerve*. 2007.

[58]. Ruberg, F. (2024). Cardiac amyloidosis due to transthyretin protein. Jama, 331(9), 778. https://doi.org/10.1001/jama.2024.0442

[59]. Ogieuhi, I. (2024). Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence. The Egyptian Heart Journal, 76(1). https://doi.org/10.1186/s43044-024-00517-y

[60]. Dasgupta, N. and Rao, R. (2020). <p>diagnosis and screening of patients with hereditary transthyretin amyloidosis (hattr): current strategies and guidelines</p>. Therapeutics and Clinical Risk Management, Volume 16, 749-758. https://doi.org/10.2147/tcrm.s185677

[61]. .Damy, T., Kristen, A., Suhr, O., Maurer, M., Planté-Bordeneuve, V., Yu, C., … & investigators, T. (2019). Transthyretin cardiac amyloidosis in continental western europe: an insight through the transthyretin amyloidosis outcomes survey (thaos). European Heart Journal, 43(5), 391-400. https://doi.org/10.1093/eurheartj/ehz173

[62]. Griffiths, D. (2020). *Introduction to Elementary Particles*. John Wiley & Sons.

[63]. Naito, T., Nakamura, K., Abe, Y., Watanabe, H., Sakuragi, S., Katayama, Y., … & Tanimoto, M. (2023). Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in japan. Esc Heart Failure, 10(3), 1896-1906. https://doi.org/10.1002/ehf2.14364

[64]. Madhani, A. (2023). Clinical penetrance of the transthyretin v122i variant in older black patients with heart failure: the scan-mp (screening for cardiac amyloidosis with nuclear imaging in minority populations) study. Journal of the American Heart Association, 12(15). https://doi.org/10.1161/jaha.122.028973

[65]. Juarez, M., Rio-Pertuz, G., Parmar, K., Bois, M., Shurmur, S., & Argueta-Sosa, E. (2022). A case of early hereditary transthyretin amyloid cardiomyopathy recognition with genetic screening: a case report. Journal of Primary Care & Community Health, 13. https://doi.org/10.1177/21501319211062682

[66]. *Heart and Neurologic Disease*. (2021). Elsevier.

[67]. Lin, W., Chattranukulchai, P., Lee, A., Lin, Y., Yu, W., Liew, H., … & Oomman, A. (2022). Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in asia. Clinical Cardiology, 45(9), 898-907. https://doi.org/10.1002/clc.23882

[68]. amyloid cardiomyopathy: distinct from wild-type transthyretin amyloidosis?. European Journal of Heart Failure, 26(2), 383-393. https://doi.org/10.1002/ejhf.3088

[69]. 69.Maestro-Benedicto, A., Vela, P., Frutos, F., Mora, N., Pomares, A., Briceño, A., … & García-Pavía, P. (2022). Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. European Journal of Heart Failure, 24(12), 2367-2373. https://doi.org/10.1002/ejhf.265871

[70]. Dubois, J. (2024). Bone tracers for transthyretin amyloid cardiomyopathy: are [99mtc]tc-dpd and [99mtc]tc-hmdp truly equivalent?.. https://doi.org/10.1101/2024.02.14.24302851

[71]. Porcari, A., Razvi, Y., Masi, A., Patel, R., Rauf, M., Hutt, D., … & Gillmore, J. (2023). Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 25(4), 515-524. https://doi.org/10.1002/ejhf.2776

[72]. Saef, J., Martyn, T., Ives, L., Roth, L., Grodin, J., Maurer, M., … & Tang, W. (2023). Predictive modeling to assess pretest probability of transthyretin gene variants based on demographic information. Circulation Heart Failure, 16(4). https://doi.org/10.1161/circheartfailure.122.009908

[73]. Mohty, D., Nasr, S., Ragy, H., Farhan, H., Fadel, B., Alayary, I., … & Ghoubar, M. (2023). Cardiac amyloidosis: a survey of current awareness, diagnostic modalities, treatment practices, and clinical challenges among cardiologists in selected middle eastern countries. Clinical Cardiology, 46(6), 648-655. https://doi.org/10.1002/clc.23985

[74]. Polimanti, R. and Nuñez, Y. (2019). Increased risk of multiple outpatient surgeries in african-american carriers of transthyretin val122ile mutation is modulated by non-coding variants. Journal of Clinical Medicine, 8(2), 269. https://doi.org/10.3390/jcm8020269

[75]. Razvi, Y., Porcari, A., Nora, C., Patel, R., Rauf, M., Masi, A., … & Gillmore, J. (2023). Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary center experience. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.1075806

[76]. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. *New England Journal of Medicine*. 2018.

[77]. García-Pavía, P., Bengel, F., Brito, D., Damy, T., Duca, F., Dorbala, S., … & Elliott, P. (2021). Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 23(6), 895-905. https://doi.org/10.1002/ejhf.2198

[78]. Kim, M., Prasad, M., Burton, Y., Kolseth, C., Zhao, Y., Chandrashekar, P., … & Masri, A. (2023). Comparative outcomes of a transthyretin amyloid cardiomyopathy cohort versus patients with heart failure with preserved ejection fraction enrolled in the topcat trial. Journal of the American Heart Association, 12(15). https://doi.org/10.1161/jaha.123.029705

[79]. Morioka, M., Takashio, S., Nishi, M., Fujiyama, A., Hirakawa, K., Hanatani, S., … & Tsujita, K. (2022). Correlation between cardiac images, biomarkers, and amyloid load in wild-type transthyretin amyloid cardiomyopathy. Journal of the American Heart Association, 11(12). https://doi.org/10.1161/jaha.121.024717

[80]. García-Pavía, P., Siepen, F., Donal, E., Lairez, O., Meer, P., Kristen, A., … & Damy, T. (2023). Phase 1 trial of antibody ni006 for depletion of cardiac transthyretin amyloid. New England Journal of Medicine, 389(3), 239-250. https://doi.org/10.1056/nejmoa2303765

[81]. Knight, D., Zumbo, G., Barcella, W., Steeden, J., Muthurangu, V., Martinez-Naharro, A., … & Fontana, M. (2019). Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. Jacc Cardiovascular Imaging, 12(5), 823-833. https://doi.org/10.1016/j.jcmg.2018.02.016

[82]. Tsai, C. (2023). Tafamidis decreased cardiac amyloidosis deposition in patients with ala97ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study. Orphanet Journal of Rare Diseases, 18(1). https://doi.org/10.1186/s13023-023-02824-0

[83]. Shah, S. (2024). Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy. Jama Cardiology, 9(1), 25. https://doi.org/10.1001/jamacardio.2023.4147

[84]. Rettl, R., Wollenweber, T., Duca, F., Binder, C., Cherouny, B., Dachs, T., … & Binder-Rodriguez, C. (2023). Monitoring tafamidis treatment with quantitative spect/ct in transthyretin amyloid cardiomyopathy. European Heart Journal - Cardiovascular Imaging, 24(8), 1019-1030. https://doi.org/10.1093/ehjci/jead030

[85]. Teng, C., Li, P., Bae, J., Pan, S., Dixon, R., & Liu, Q. (2020). Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy. Clinical Cardiology, 43(11), 1223-1231. https://doi.org/10.1002/clc.23434

[86]. Elkefi, S. and Asan, O. (2023). The impact of patient-centered care on cancer patients' qoc, self-efficacy, and trust towards doctors: analysis of a national survey. Journal of Patient Experience, 10. https://doi.org/10.1177/23743735231151533

[87]. Greenhalgh, J., Gooding, K., Gibbons, E., Dalkin, S., Wright, J., Valderas, J., … & Black, N. (2018). How do patient reported outcome measures (proms) support clinician-patient communication and patient care? a realist synthesis. Journal of Patient-Reported Outcomes, 2(1). https://doi.org/10.1186/s41687-018-0061-6

[88]. Henselmans, I., Laarhoven, H., Haes, H., Tokat, M., Engelhardt, E., Maarschalkerweerd, P., … & Smets, E. (2018). Training for medical oncologists on shared decision-making about palliative chemotherapy: a randomized controlled trial. The Oncologist, 24(2), 259-265. https://doi.org/10.1634/theoncologist.2018-0090

[89]. Poitras, M., Maltais, M., Bestard-Denommé, L., Stewart, M., & Fortin, M. (2018). What are the effective elements in patient-centered and multimorbidity care? a scoping review. BMC Health Services Research, 18(1). https://doi.org/10.1186/s12913-018-3213-8

[90]. Saul, J., Holder, S., & Lokey, J. (2018). Employing the patient-centered collaborative care approach: a case study of complex geriatric patient with psychopathalogy of treatment resistant depression and primary hyperparathyroidism.. mental-health-aging, 02(01). https://doi.org/10.35841/mental-health-aging.2.1.18-23

[91]. Barnes, S., Steiguer, A., Gelman, D., & Parade, S. (2020). Implementation of measurement-based care in a child partial hospital program. The Brown University Child and Adolescent Behavior Letter, 36(7), 1-7. https://doi.org/10.1002/cbl.30475

[92]. Pirhonen, L., Gyllensten, H., Olofsson, E., Fors, A., Ali, L., Ekman, I., … & Bolin, K. (2020). The cost-effectiveness of person-centred care provided to patients with chronic heart failure and/or chronic obstructive pulmonary disease. Health Policy Open, 1, 100005. https://doi.org/10.1016/j.hpopen.2020.100005

[93]. Nagineviciute, M. (2023). Woman-centered care: standardized outcomes measure. Medicina, 59(9), 1537. https://doi.org/10.3390/medicina59091537

[94]. Reese, R., Duncan, B., Kodet, J., Brown, H., Meiller, C., Farook, M., … & Bohanske, R. (2018). Patient feedback as a quality improvement strategy in an acute care, inpatient unit: an investigation of outcome and readmission rates.. Psychological Services, 15(4), 470-476. https://doi.org/10.1037/ser0000163

[95]. Kersting, C., Kneer, M., & Barzel, A. (2020). Patient-relevant outcomes: what are we talking about? a scoping review to improve conceptual clarity. BMC Health Services Research, 20(1). https://doi.org/10.1186/s12913-020-05442-9'

[96]. Harris, V., Links, A., Walsh, J., Schoo, D., Lee, A., Tunkel, D., … & Boss, E. (2018). A systematic review of race/ethnicity and parental treatment decision-making. Clinical Pediatrics, 57(12), 1453-1464. https://doi.org/10.1177/0009922818788307

[97]. Ponti, L. (2023). Caregiver's psychological well-being and quality of relationship with cardiac amyloidosis patients. Psychology Health & Medicine, 29(1), 66-78. https://doi.org/10.1080/13548506.2023.2280463

[98]. Rintell, D., Heath, D., Menendez, F., Cross, E., Cross, T., Knobell, V., … & Kalmykov, E. (2020). Patient and family experience with transthyretin amyloid cardiomyopathy (attr-cm) and polyneuropathy (attr-pn) amyloidosis: results of two focus groups.. https://doi.org/10.21203/rs.3.rs-48013/v2

[99]. Rintell, D., Heath, D., Mendendez, F., Cross, E., Cross, T., Knobel, V., … & Fox, J. (2021). Patient and family experience with transthyretin amyloid cardiomyopathy (attr-cm) and polyneuropathy (attr-pn) amyloidosis: results of two focus groups. Orphanet Journal of Rare Diseases, 16(1). https://doi.org/10.1186/s13023-021-01706-7

[100]. Ponti, L. (2023). Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1238843

[101]. Saef, J., Martyn, T., Ives, L., Roth, L., Grodin, J., Maurer, M., … & Tang, W. (2023). Predictive modeling to assess pretest probability of transthyretin gene variants based on demographic information. Circulation Heart Failure, 16(4). https://doi.org/10.1161/circheartfailure.122.009908

[102]. Kroi, F., Fischer, N., Gezin, A., Hashim, M., & Rozenbaum, M. (2020). Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. Cardiology and Therapy, 10(1), 41-55. https://doi.org/10.1007/s40119-020-00205-3

[103]. Maurer, M., Bokhari, S., Damy, T., Dorbala, S., Drachman, B., Fontana, M., … & Merlini, G. (2019). Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circulation Heart Failure, 12(9). https://doi.org/10.1161/circheartfailure.119.006075

[104]. Merino-Merino, A. (2023). Utility of genetic testing in patients with transthyretin amyloid cardiomyopathy: a brief review. Biomedicines, 12(1), 25. https://doi.org/10.3390/biomedicines12010025

[105]. Davies, D., Redfield, M., Scott, C., Minamisawa, M., Grogan, M., Dispenzieri, A., … & AbouEzzeddine, O. (2022). A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. Jama Cardiology, 7(10), 1036. https://doi.org/10.1001/jamacardio.2022.1781

[106]. Devesa, A., Blasco, A., Lázaro, A., Askari, E., Lapeña, G., Talavera, S., … & Aceña, Á. (2021). Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. Esc Heart Failure, 8(4), 2856-2865. https://doi.org/10.1002/ehf2.13360

[107]. Elliott, P., Drachman, B., Gottlieb, S., Hoffman, J., Hummel, S., Lenihan, D., … & Shah, S. (2022). Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circulation Heart Failure, 15(1). https://doi.org/10.1161/circheartfailure.120.008193

[108]. Moya, A. (2023). Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records. Esc Heart Failure, 10(6), 3483-3492. https://doi.org/10.1002/ehf2.14517

[109]. Rozenbaum, M., Large, S., Bhambri, R., Stewart, M., Whelan, J., Doornewaard, A., … & Nativi-Nicolau, J. (2021). Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (attr-cm): a targeted literature review. Cardiology and Therapy, 10(1), 141-159. https://doi.org/10.1007/s40119-021-00219-5

[110]. Rio-Pertuz, G., Jenkins, L., Sethi, P., & Argueta-Sosa, E. (2022). Wild transthyretin amyloid cardiomyopathy recognition with noninvasive strategies: a case report and diagnostic approach for transthyretin-related cardiomyopathy. The Southwest Respiratory and Critical Care Chronicles, 10(42), 16-21. https://doi.org/10.12746/swrccc.v10i42.999

[111]. Nativi-Nicolau, J., Siu, A., Dispenzieri, A., Maurer, M., Rapezzi, C., Kristen, A., … & Mueller, C. (2021). Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey. Jacc Cardiooncology, 3(4), 537-546. https://doi.org/10.1016/j.jaccao.2021.08.009

[112]. Burton, A., Castaño, A., Bruno, M., Riley, S., Schumacher, J., Sultan, M., … & Patel, J. (2021). Drug discovery and development in rare diseases: taking a closer look at the tafamidis story. Drug Design Development and Therapy, Volume 15, 1225-1243. https://doi.org/10.2147/dddt.s289772

[113]. Yokoyama, T. and Mizuguchi, M. (2020). Transthyretin amyloidogenesis inhibitors: from discovery to current developments. Journal of Medicinal Chemistry, 63(23), 14228-14242. https://doi.org/10.1021/acs.jmedchem.0c00934

[114]. Shintani, Y., Okada, A., Morita, Y., Hamatani, Y., Amano, M., Takahama, H., … & Izumi, C. (2018). Monitoring treatment response to tafamidis by serial native t1 and extracellular volume in transthyretin amyloid cardiomyopathy. Esc Heart Failure, 6(1), 232-236. https://doi.org/10.1002/ehf2.12382

[115]. Damrauer, S., Chaudhary, K., Cho, J., Liang, L., Argulian, E., Chan, L., … & Do, R. (2019). Association of the v122i hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of african or hispanic/latino ancestry. Jama, 322(22), 2191. https://doi.org/10.1001/jama.2019.17935

[116]. Chu, X., Wang, M., Tang, R., Huang, Y., Yu, J., Cao, Y., … & Meng, L. (2022). Clinical and biochemical characterization of hereditary transthyretin amyloidosis caused by e61k mutation. Frontiers in Molecular Neuroscience, 15. https://doi.org/10.3389/fnmol.2022.1003303

[117]. Müller, M., Butler, J., & Heidecker, B. (2020). Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy?. European Journal of Heart Failure, 22(1), 39-53. https://doi.org/10.1002/ejhf.1695

[118]. Pinheiro, F., Pallarès, I., Peccati, F., Sánchez-Morales, A., Varejão, N., Bezerra, F., … & Ventura, S. (2022). Development of a highly potent transthyretin amyloidogenesis inhibitor: design, synthesis, and evaluation. Journal of Medicinal Chemistry, 65(21), 14673-14691. https://doi.org/10.1021/acs.jmedchem.2c01195
[119]. Eicher, J., Audia, S., & Damy, T. (2020). L'amylose cardiaque à transthyrétine. La Revue De Médecine Interne, 41(10), 673-683. https://doi.org/10.1016/j.revmed.2020.07.002
[120]. Mohankumar, A., Kalaiselvi, D., Thiruppathi, G., Sivaramakrishnan, M., Vijayakumar, S., Suresh, R., … & Sundararaj, P. (2022). Santalol isomers inhibit transthyretin amyloidogenesis and associated pathologies in caenorhabditis elegans. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.924862
[121]. Adams, D., González-Duarte, A., O'Riordan, W., Yang, W., Ueda, M., Kristen, A., … & Suhr, O. (2018). Patisiran, an rnai therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine, 379(1), 11-21. https://doi.org/10.1056/nejmoa1716153
[122]. Dohrn, M., Ihne, S., Hegenbart, U., Medina, J., Züchner, S., Coelho, T., … & Hahn, K. (2020). Targeting transthyretin - mechanism-based treatment approaches and future perspectives in hereditary amyloidosis. Journal of Neurochemistry, 156(6), 802-818. https://doi.org/10.1111/jnc.15233
[123]. Joshi, P. (2023). Treating alzheimer's and attr using crispr-cas9 to target amyloidosis. Journal of Student Research, 12(3). https://doi.org/10.47611/jsrhs.v12i3.4806
[124]. Aimo, A., Castiglione, V., Rapezzi, C., Franzini, M., Panichella, G., Vergaro, G., … & Emdin, M. (2022). Rna-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 19(10), 655-667. https://doi.org/10.1038/s41569-022-00683-z
[125]. Kotit, S. (2023). Lessons from the first-in-human in vivo crispr/cas9 editing of the ttr gene by ntla-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy. Global Cardiology Science and Practice, 2023(1). https://doi.org/10.21542/gcsp.2023.4
[126]. Tomasoni, D., Bonfioli, G., Aimo, A., Adamo, M., Canepa, M., Lombardi, C., … & Metra, M. (2023). Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1154594